Key Points
- CAO Louise Frederika Kooij sold 32,612 shares on January 28 at $31.80 for $1,037,061.60, leaving her with 24,353 shares — a reported 57.25% reduction in her position.
- Across multiple transactions from late December through January she sold approximately $10.04 million of NewAmsterdam Pharma stock.
- NewAmsterdam Pharma trades with a market cap of about $3.56 billion, has negative earnings and margins, but carries a consensus analyst rating of "Moderate Buy" with a $47 target price.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the sale, the chief accounting officer directly owned 24,353 shares of the company's stock, valued at $774,425.40. This represents a 57.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Louise Frederika Kooij also recently made the following trade(s):
- On Tuesday, January 27th, Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.62, for a total value of $1,298,797.92.
- On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.78, for a total value of $1,127,632.00.
- On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.75, for a total value of $1,288,305.00.
- On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $88,012.75.
- On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
- On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57.
- On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48.
NewAmsterdam Pharma Stock Performance
NAMS opened at $31.44 on Friday. The firm's fifty day moving average is $35.20 and its two-hundred day moving average is $31.25. The firm has a market cap of $3.56 billion, a PE ratio of -15.34 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $42.00.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.03). The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. Equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.
Wall Street Analyst Weigh In
NAMS has been the subject of several research analyst reports. Royal Bank Of Canada increased their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 21st. The Goldman Sachs Group upped their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a "neutral" rating in a report on Tuesday, December 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Citigroup boosted their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a "buy" rating in a research report on Friday, October 17th. Finally, Leerink Partners reaffirmed an "outperform" rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $47.00.
View Our Latest Analysis on NewAmsterdam Pharma
Institutional Investors Weigh In On NewAmsterdam Pharma
Several hedge funds have recently added to or reduced their stakes in the business. Capital World Investors boosted its position in NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company's stock worth $279,358,000 after purchasing an additional 1,434,986 shares during the period. Jennison Associates LLC lifted its stake in shares of NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company's stock worth $119,407,000 after buying an additional 1,252,451 shares during the last quarter. Duquesne Family Office LLC boosted its holdings in shares of NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company's stock worth $54,710,000 after buying an additional 1,091,525 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after buying an additional 1,062,359 shares during the last quarter. Finally, Maverick Capital Ltd. raised its holdings in NewAmsterdam Pharma by 178.8% in the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company's stock valued at $27,742,000 after acquiring an additional 982,405 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
